Abelacimab is named as a drug or biological intervention in 2 clinical trials in our USA, UK, India and China trial registers, 1 of which is recruiting. The lead sponsor is Anthos Therapeutics, Inc.. Registered phases: Phase 3 and Phase 2. Conditions studied include Atrial Fibrillation (AF); Stroke.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05712200 | Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) (ClinicalTrials.gov ↗) Atrial Fibrillation (AF) |
Phase 3 | Recruiting |
| NCT04755283 | Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation (ClinicalTrials.gov ↗) Atrial Fibrillation (AF), Stroke |
Phase 2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Atrial Fibrillation (AF) | 2 |
| Stroke | 1 |
| Lead sponsor | Trials |
|---|---|
| Anthos Therapeutics, Inc. | 2 |
| Register | Abelacimab trials |
|---|---|
| Clinical trials in USA | 2 |
| Clinical trials in UK | 1 |
| Clinical trials in India | 1 |
| Clinical trials in China | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Abelacimab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Abelacimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.